This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pfizer Provides Grants for Antibiotic Research

Oct 09, 2012

Pfizer Animal Health is seeking research proposals to support the continued study of the clinical efficacy of DRAXXIN (tulathromycin) Injectable Solution, a macrolide for the treatment of swine respiratory disease (SRD), the leading cause of swine mortality in the United States.

Pfizer Animal Health will provide up to four grants, $100,000 in total, for clinical research on the use of DRAXXIN as part of an overall disease treatment and control plan that demonstrates a direct benefit to swine health. DRAXXIN will be provided to study investigators at no cost.

“DRAXXIN has consistently proven to be an effective tool in swine health management,” says Shelley Stanford, DVM, director, U.S. Pork Technical Services at Pfizer. “Through these research grants, we are seeking to further our understanding of DRAXXIN's real world efficacy and its practical uses.”

The deadline for submission of grant proposals is Nov. 15, 2012. Proposals are only being accepted electronically. All applicants must be current university staff, advanced study students at universities or practicing doctors of veterinary medicine. Proposals will be evaluated on their direct clinical applicability, the potential to enhance the treatment of pigs, relevance to existing scientific knowledge and practical study feasibility.

Complete criteria and proposal requirements can be found at www.pfizerpork.com/draxxin. A Pfizer Animal Health committee will review applications and alert recipients in December 2012.

DRAXXIN was approved in the United States in 2005. It treats the five most common bacterial causes of SRD, including Mycoplasma pneumonia, and controls SRD associated with three bacterial causes in groups of pigs where SRD has been diagnosed. Its one-dose formula provides nine days of extended therapy and effectiveness while minimizing labor. DRAXXIN also helps reduce shedding, which decreases disease transmission and mortality.